These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 14607217)

  • 21. Molecular basis of co-targeting prostate tumor and stroma.
    Yeung F; Chung LW
    J Cell Biochem Suppl; 2002; 38():65-72. PubMed ID: 12046851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer.
    Joesting MS; Perrin S; Elenbaas B; Fawell SE; Rubin JS; Franco OE; Hayward SW; Cunha GR; Marker PC
    Cancer Res; 2005 Nov; 65(22):10423-30. PubMed ID: 16288033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.
    Xie X; Zhao X; Liu Y; Zhang J; Matusik RJ; Slawin KM; Spencer DM
    Cancer Res; 2001 Sep; 61(18):6795-804. PubMed ID: 11559553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy.
    Li X; Liu YH; Zhang YP; Zhang S; Pu X; Gardner TA; Jeng MH; Kao C
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5463-73. PubMed ID: 17875776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer.
    Cheng WS; Kraaij R; Nilsson B; van der Weel L; de Ridder CM; Tötterman TH; Essand M
    Mol Ther; 2004 Aug; 10(2):355-64. PubMed ID: 15294182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy.
    Thorne SH; Tam BY; Kirn DH; Contag CH; Kuo CJ
    Mol Ther; 2006 May; 13(5):938-46. PubMed ID: 16469543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer.
    Magnusson MK; Kraaij R; Leadley RM; De Ridder CM; van Weerden WM; Van Schie KA; Van der Kroeg M; Hoeben RC; Maitland NJ; Lindholm L
    Hum Gene Ther; 2012 Jan; 23(1):70-82. PubMed ID: 21875358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration.
    Pariente N; Morizono K; Virk MS; Petrigliano FA; Reiter RE; Lieberman JR; Chen IS
    Mol Ther; 2007 Nov; 15(11):1973-81. PubMed ID: 17653099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines.
    Lee SE; Jin RJ; Lee SG; Yoon SJ; Park MS; Heo DS; Choi H
    Anticancer Res; 2000; 20(1A):417-22. PubMed ID: 10769689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer.
    Eastham JA; Grafton W; Martin CM; Williams BJ
    J Urol; 2000 Sep; 164(3 Pt 1):814-9. PubMed ID: 10953161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector.
    Lu ZH; Kaliberov S; Sohn RE; Kaliberova L; Du Y; Prior JL; Leib DJ; Chauchereau A; Sehn JK; Curiel DT; Arbeit JM
    Oncotarget; 2017 Feb; 8(7):12272-12289. PubMed ID: 28103576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
    Li Y; McCadden J; Ferrer F; Kruszewski M; Carducci M; Simons J; Rodriguez R
    Cancer Res; 2002 May; 62(9):2576-82. PubMed ID: 11980652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Replication-competent Ad11p vector (RCAd11p) efficiently transduces and replicates in hormone-refractory metastatic prostate cancer cells.
    Sandberg L; Papareddy P; Silver J; Bergh A; Mei YF
    Hum Gene Ther; 2009 Apr; 20(4):361-73. PubMed ID: 19199789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene promoter methylation in prostate tumor-associated stromal cells.
    Hanson JA; Gillespie JW; Grover A; Tangrea MA; Chuaqui RF; Emmert-Buck MR; Tangrea JA; Libutti SK; Linehan WM; Woodson KG
    J Natl Cancer Inst; 2006 Feb; 98(4):255-61. PubMed ID: 16478744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor formation of prostate cancer cells influenced by stromal cells from the transitional or peripheral zones of the normal prostate.
    Zhao FJ; Han BM; Yu SQ; Xia SJ
    Asian J Androl; 2009 Mar; 11(2):176-82. PubMed ID: 19122679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adeno-associated virus-delivered short hairpin-structured RNA for androgen receptor gene silencing induces tumor eradication of prostate cancer xenografts in nude mice: a preclinical study.
    Sun A; Tang J; Terranova PF; Zhang X; Thrasher JB; Li B
    Int J Cancer; 2010 Feb; 126(3):764-74. PubMed ID: 19642108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2: enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model.
    Raikwar SP; Temm CJ; Raikwar NS; Kao C; Molitoris BA; Gardner TA
    Mol Ther; 2005 Dec; 12(6):1091-100. PubMed ID: 16169279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.
    Li X; Zhang YP; Kim HS; Bae KH; Stantz KM; Lee SJ; Jung C; Jiménez JA; Gardner TA; Jeng MH; Kao C
    Cancer Res; 2005 Mar; 65(5):1941-51. PubMed ID: 15753394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New prospectives of prostate cancer gene therapy: molecular targets and animal models.
    Hsieh CL; Chung LW
    Crit Rev Eukaryot Gene Expr; 2001; 11(1-3):77-120. PubMed ID: 11693967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adenovirus-mediated expression of TIMP-1 and TIMP-2 in bone inhibits osteolytic degradation by human prostate cancer.
    Deng X; He G; Levine A; Cao Y; Mullins C
    Int J Cancer; 2008 Jan; 122(1):209-18. PubMed ID: 17847032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.